Your Federal Quarterly Tax Payments are due April 15th Get Help Now >>

HIV by janejack

VIEWS: 13 PAGES: 8

GBI Research, the leading business intelligence provider, has released its latest research, “HIV/AIDS Therapeutics Market to 2017 - Superior Combination Therapies and Decreasing Mortality to Sustain Market Growth Despite Major Patent Expiries"

More Info
									HIV/AIDS Therapeutics Market to 2017 - Superior Combination Therapies and
Decreasing Mortality to Sustain Market Growth
Published: October 2011
Price: $3500

Report Summary


GBI Research, the leading business intelligence provider, has released its latest research,
“HIV/AIDS Therapeutics Market to 2017 - Superior Combination Therapies and Decreasing
Mortality to Sustain Market Growth Despite Major Patent Expiries”. It provides in-depth
analysis of the unmet needs, drivers and barriers that affect the global HIV/AIDS
therapeutics market. The report analyzes the markets for HIV/AIDS in the US, the top
five European countries (the UK, Germany, France, Italy and Spain) and Japan. Treatment
usage pattern and annual cost of treatment are forecast until 2017 for key geographies in
the leading therapeutic segments. Furthermore, the report provides competitive
benchmarking for the leading companies and analyzes the mergers and acquisitions (M&A)
and licensing agreements that shape the global markets. The report is built using data and
information sourced from proprietary databases, primary and secondary research and in-
house      analysis    by     GBI     Research‟s     team      of    industry      experts.

Scope
   The scope of this report includes:
   Annualized market data for the HIV therapeutics market from 2002 to 2010, forecast
    until 2017.
   Analysis of the HIV therapeutics market in the leading geographies of the world: the US,
    the UK, Germany, France, Italy, Spain, and Japan.
   Market characterization of the HIV therapeutics market including market size, annual
    cost of therapy, sales volume and treatment usage patterns.
   Key drivers and barriers that have a significant impact on the market.
   Coverage of pipeline molecules in various phases of drug development.
   Competitive benchmarking of leading companies. The key companies studied in this
    report are Gilead Sciences Inc, GlaxoSmithKline, Bristol-Myers Squibb, Abbott
    Laboratories, Merck & Co and Pfizer Inc.
   Key M&A activities, licensing agreements, that have taken place between 2008 and 2009
    in the global HIV therapeutics market.


Reasons to Buy


   The report will assist business development and marketing executives to strategize their
    product launches, by allowing them to:
   Align product portfolio to the markets with high growth potential.
   Develop market entry and market expansion strategies by identifying the leading
    therapeutic segments and geographic markets poised for strong growth.
   Reinforce R&D pipelines by identifying new target mechanisms which can produce first in
    class molecules with more efficiency and better safety.
   Develop key strategic initiatives by understanding key focus areas of leading companies.
   Exploit in-licensing and out-licensing opportunities by identifying products that could fill
    portfolio gaps.

Browse all : Market Research Report

Table of Contents1 Table of Contents


1.1 List of Tables
1.2 1.2 List of Figures

2 HIV/AIDS Therapeutics Market to 2017 - Introduction


2.1 GBI Research Report Guidance
3 HIV/AIDS Therapeutics Market to 2017 - Global Overview
3.1 Disease Overview
3.2 Market Overview
3.3 Overview of Recent Research Advancements in HIV/AIDS Therapy

4 HIV/AIDS Therapeutics Market to 2017 - Market Characterization

4.1 Market Forecasts
4.1.1 Branded Versus Generics
4.2 Annual Cost of Therapy
4.3 Treatment Usage Patterns
4.3.1 Diseased Population
4.3.2 Treatment Seeking Population
4.3.3 Diagnosis Population
4.3.4 Prescription Population
4.4 Geographical Distribution
4.5 Drivers and Restraints
4.6 Market Drivers
4.6.1 Increase in Awareness Levels of Disease Progression will Lead to an Increase in
Treatment Seeking and Diagnosed Populations
4.6.2 New Product Launches will Increase Uptake and Drive the Market
4.6.3 Increase in Drug Prices will Drive Growth and Lessen the Impact of Generics
4.7 Market Restraints
4.7.1 Patent Expirations and the Subsequent Entry of Generics will Negatively Impact the
Market
4.7.2 Social Stigma Associated with HIV Leads to Low Treatment Seeking Rate
4.7.3 Rigorous and Complex Treatment Regimes Result in Poor Patient Compliance Leading
to a Reduction in Drug Volumes

5 HIV/AIDS Therapeutics Market to 2017 - The US


5.1 Market Forecasts
5.2 Annual Cost of Therapy
5.3 Treatment Usage Patterns
5.3.1 Diseased Population
5.3.2 Treatment Seeking Population
5.3.3 Diagnosis Population
5.3.4 Prescription Population

6 HIV/AIDS Therapeutics Market to 2017- Top Five European Countries


6.1 Market Forecasts
6.1.1 Revenue by Country
6.2 Annual Cost of Therapy
6.3 Treatment Usage Patterns
6.3.1 Diseased Population
6.3.2 Treatment Seeking Population
6.3.3 Diagnosis Population
6.3.4 Prescription Population

7 HIV/AIDS Therapeutics Market to 2017 - Japan


7.1 Market Forecasts
7.2 Annual Cost of Therapy
7.3 Treatment Usage Patterns
7.3.1 Diseased Population
7.3.2 Treatment Seeking Population
7.3.3 Diagnosis Population
7.3.4 Prescription Population

8 HIV/AIDS Therapeutics Market to 2017 - Pipeline Assessment


8.1 Major Classes of Drugs
8.1.1 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (NRTIs)
8.1.2 Non-Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
8.1.3 Protease Inhibitors
8.1.4 Viral Fusion (or Entry) Inhibitors
8.1.5 HIV Integrase Strand Transfer Inhibitors
8.1.6 Multi-Class Combination Products
8.2 Pipeline Overview
8.3 Strategic Pipeline Assessment
8.4 HIV/AIDS Therapeutics Pipeline - Pipeline by Clinical Phases of Development
8.4.1 HIV/AIDS Therapeutics - Phase III Clinical Pipeline
8.4.2 HIV/AIDS Therapeutics - Phase II Clinical Pipeline
8.4.3 HIV/AIDS Therapeutics - Phase I Clinical Pipeline
8.4.4 HIV/AIDS - Preclinical Pipeline
8.4.5 HIV/AIDS - Discovery Clinical Pipeline
8.5 HIV/AIDS Therapeutics - Pipeline by Mechanism of Action
8.6 HIV/AIDS Therapeutics - Most Promising Drugs under Clinical Development

9 HIV/AIDS Therapeutics Market to 2017 - Competitive Landscape


9.1 Major Company Profiles
9.1.1 Gilead Sciences, Inc
9.1.2 GlaxoSmithKline (GSK)
9.1.3 Bristol-Myers Squibb (BMS)
9.1.4 Abbott Laboratories
9.1.5 Merck
9.1.6 Pfizer

10 HIV/AIDS Therapeutics Market to 2017 - Licencing and Partnership Deals


10.1 Global HIV/AIDS Market
10.1.1 Overview: Deals by Type and Geography
10.1.2 Mergers and Acquisitions
10.1.3 Licensing Agreements

11 HIV/AIDS Therapeutics Market to 2017 - Appendix


11.1 Market Definitions
11.2 Abbreviations
11.3 Research Methodology
11.3.1 Coverage
11.3.2 Secondary Research
11.3.3 Primary Research
11.3.4 Forecasts
11.3.5 Expert Panel Validation
11.4 Contact Us
11.5 Disclaimer
11.6 Sources

List of Tables

Table   1:   HIV/AIDS   Therapeutics   Market,   Global,   Revenue ($m), 2002-2010
Table   2:   HIV/AIDS   Therapeutics   Market,   Global,   Revenue Forecasts ($m), 2010-2017
Table   3:   HIV/AIDS   Therapeutics   Market,   Global,   Annual Cost of Therapy ($), 2002-2010
Table   4:   HIV/AIDS   Therapeutics   Market,   Global,   Annual Cost of Therapy ($), 2010-2017
Table   5:   HIV/AIDS   Therapeutics   Market,   Global,   Treatment Usage Patterns („000), 2002-
2010
Table   6: HIV/AIDS Therapeutics Market, Global, Treatment Usage Patterns („000), 2010-
2017
Table   7: HIV/AIDS Therapeutics Market, Global, Diseased Population („000), 2002-2010
Table   8: HIV/AIDS Therapeutics Market, Global, Diseased Population („000), 2010-2017
Table 9: HIV/AIDS Therapeutics Market, Global, Treatment Seeking Population („000),
2002-2010
Table 10: HIV/AIDS Therapeutics Market, Global, Treatment Seeking Population („000),
2010-2017
Table 11: HIV/AIDS Therapeutics Market, Global, Diagnosis Population, 2002-2010
Table 12: HIV/AIDS Therapeutics Market, Global, Diagnosis Population, 2010-2017
Table 13: HIV/AIDS Therapeutics Market, Global, Prescription Population, 2002-2010
Table 14: HIV/AIDS Therapeutics Market, Global, Prescription Population, 2010-2017
Table 15: HIV/AIDS Therapeutics Market, Global, Geographical Distribution of Revenues
($m), 2002-2010
Table 16: HIV/AIDS Therapeutics Market, Global, Geographical Distribution of Revenues
($m), 2010-2017
Table 17: HIV/AIDS Therapeutics Market, Global, Key Drugs Going Off Patent, 2009-2017
Table 18: HIV/AIDS Therapeutics Market, the US, Revenues ($m), 2002-2010
Table 19: HIV/AIDS Therapeutics Market, the US, Revenue ($m), 2010-2017
Table 20: HIV/AIDS Therapeutics Market, the US, Annual Cost of Therapy ($), 2002-2010
Table 21: HIV/AIDS Therapeutics Market, the US, Annual Cost of Therapy ($), 2010-2017
Table 22: HIV/AIDS Therapeutics Market, the US, Treatment Usage Patterns („000), 2002-
2010
Table 23: HIV/AIDS Therapeutics Market, US, Treatment Usage Patterns („000), 2010-2017
Table 24: HIV/AIDS Therapeutics Market, the US, Diseased Population („000), 2002-2010
Table 25: HIV/AIDS Therapeutics Market, the US, Diseased Population („000), 2010-2017
Table 26: HIV/AIDS Therapeutics Market, the US, Treatment Seeking Population („000),
2002-2010
Table 27: HIV/AIDS Therapeutics Market, the US, Treatment Seeking Population („000),
2010-2017
Table 28: HIV/AIDS Therapeutics Market, US, Diagnosis Population („000), 2002-2010
Table 29: HIV/AIDS Therapeutics Market, US, Diagnosis Population („000), 2010-2017
Table 30: HIV/AIDS Therapeutics Market, the US, Prescription Population („000), 2002-2010
Table 31: HIV/AIDS Therapeutics Market, the US, Prescription Population („000), 2010-2017
Table 32: HIV/AIDS Therapeutics Market, Top Five European Countries, Revenues ($m),
2002-2010
Table 33: HIV/AIDS Therapeutics Market, Top Five European Countries, Revenues ($m),
2010-2017
Table 34: HIV/AIDS Therapeutics Market, Top Five European Countries, Revenue by Country
($m), 2002-2010
Table 35: HIV/AIDS Therapeutics Market, Top Five European Countries, Revenue by Country
($m), 2010-2017
Table 36: HIV/AIDS Therapeutics Market, Top Five European Countries, Annual Cost of
Therapy ($), 2002-2010
Table 37: HIV/AIDS Therapeutics Market, Top Five European Countries, Annual Cost of
Therapy ($), 2010-2017
Table 38: HIV/AIDS Therapeutics Market, Top Five European Countries, Treatment Usage
Patterns, 2002-2010
Table 39: HIV/AIDS Therapeutics Market, Top Five European Countries, Treatment Usage
Patterns, 2010-2017
Table 40: HIV/AIDS Therapeutics Market, Top Five European Countries, Diseased Population
(‟000), 2002-2010
Table 41: HIV/AIDS Therapeutics Market, Top Five European Countries, Diseased Population
(‟000), 2010-2017
Table 42: HIV/AIDS Therapeutics   Market, Top Five European Countries, Treatment Seeking
Population (‟000), 2002-2010
Table 43: HIV/AIDS Therapeutics   Market, Top Five European Countries, Treatment Seeking
Population (‟000), 2010-2017
Table 44: HIV/AIDS Therapeutics   Market, Top Five European Countries, Diagnosis
Population (‟000), 2002-2010
Table 45: HIV/AIDS Therapeutics   Market, Top Five European Countries, Diagnosis
Population (‟000), 2010-2017
Table 46: HIV/AIDS Therapeutics   Market, Top Five European Countries, Prescription
Population (‟000), 2002-2010
Table 47: HIV/AIDS Therapeutics   Market, Top Five European Countries, Prescription
Population (‟000), 2010-2017
Table 48: HIV/AIDS Therapeutics   Market,   Japan,   Revenues ($m), 2002-2010
Table 49: HIV/AIDS Therapeutics   Market,   Japan,   Revenues ($m), 2010-2017
Table 50: HIV/AIDS Therapeutics   Market,   Japan,   Annual Cost of Therapy ($), 2002-2010
Table 51: HIV/AIDS Therapeutics   Market,   Japan,   Annual Cost of Therapy ($), 2010-2017
Table 52: HIV/AIDS Therapeutics   Market,   Japan,   Treatment Usage Patterns („000), 2002-
2010
Table 53: HIV/AIDS Therapeutics   Market, Japan, Treatment Usage Patterns („000), 2010-
2017
Table 54: HIV/AIDS Therapeutics   Market, Japan, Diseased Population (‟000), 2002-2010
Table 55: HIV/AIDS Therapeutics   Market, Japan, Diseased Population (‟000), 2010-2017
Table 56: HIV/AIDS Therapeutics   Market, Japan, Treatment Seeking Population (‟000),
2002-2010
Table 57: HIV/AIDS Therapeutics   Market, Japan, Treatment Seeking Population (‟000),
2010-2017
Table 58: HIV/AIDS Therapeutics   Market,   Japan, Diagnosis Population (‟000), 2002-2010
Table 59: HIV/AIDS Therapeutics   Market,   Japan, Diagnosis Population (‟000), 2010-2017
Table 60: HIV/AIDS Therapeutics   Market,   Japan, Prescription Population (‟000), 2002-2010
Table 61: HIV/AIDS Therapeutics   Market,   Japan, Prescription Population (‟000), 2010-2017
Table 62: HIV/AIDS Therapeutics   Market,   Global, Different Classes of Drugs
Table 63: HIV/AIDS Therapeutics   Market,   Phase III Pipeline, 2010
Table 64: HIV/AIDS Therapeutics   Market,   Phase II Pipeline, 2010
Table 65: HIV/AIDS Therapeutics   Market,   Phase I Pipeline, 2010
Table 66: HIV/AIDS Therapeutics   Market,   Preclinical Pipeline, 2010
Table 67: HIV/AIDS Therapeutics   Market,   Discovery Clinical Pipeline, 2010
Table 68: HIV/AIDS Therapeutics   Market,   Most Promising Drugs Under Clinical
Development, 2010
Table 69: HIV/AIDS Therapeutics   Market, Global, Benchmarking Analysis for Top Three
Companies, 2010
Table 70: HIV/AIDS Therapeutics   Market, Global, Licensing Agreements for Drugs in the
Preclinical Stage, 2009
Table 71: HIV/AIDS Therapeutics   Market, Global, Licensing Agreements for Drugs in Phase
II, 2009
Table 72: HIV/AIDS Therapeutics   Market, Global, Licensing Agreements for Drugs in Phase
III, 2009
Table 73: HIV/AIDS Therapeutics   Market, Global, Licensing Agreements for Approved Drugs,
2009

List of Figures
Figure 1: HIV/AIDS Therapeutics Market, Global, HIV Treatment Flow Algorithm, 2011
Figure 2: HIV/AIDS Therapeutics Market, Global, Market Overview, 2010
Figure 3: HIV/AIDS Therapeutics Market, Global, Revenue ($m), 2002-2017
Figure 4: HIV/AIDS Therapeutics Market, Global, Revenue Segmentation, 2010-2017
Figure 5: HIV/AIDS Therapeutics Market, Global, Annual Cost of Therapy ($), 2002-2017
Figure 6: HIV/AIDS Therapeutics Market, Global, Treatment Usage Patterns, 2002-2017
Figure 7: HIV/AIDS Therapeutics Market, Global, Diseased Population, 2002-2017
Figure 8: HIV/AIDS Therapeutics Market, Global, Treatment Seeking Population, 2002-2017
Figure 9: HIV/AIDS Therapeutics Market, Global, Diagnosis Population, 2002-2017
Figure 10: HIV/AIDS Therapeutics Market, Global, Prescription Population, 2002-2017
Figure 11: HIV/AIDS Therapeutics Market, Global, Geographical Distribution of Revenues
($m), 2002-2017
Figure 12: HIV/AIDS Therapeutics Market, the US, Revenue ($m), 2002-2017
Figure 13: HIV/AIDS Therapeutics Market, the US, Annual Cost of Therapy ($), 2002-2017
Figure 14: HIV/AIDS Therapeutics Market, the US, Treatment Usage Patterns, 2002-2017
Figure 15: HIV/AIDS Therapeutics Market, the US, Diseased Population, 2002-2017
Figure 16: HIV/AIDS Therapeutics Market, the US, Treatment Seeking Population, 2002-
2017
Figure 17: HIV/AIDS Therapeutics Market, US, Diagnosis Population, 2002-2017
Figure 18: HIV/AIDS Therapeutics Market, the US, Prescription Population, 2002-2017
Figure 19: HIV/AIDS Therapeutics Market, Top Five European Countries, Revenue ($m),
2002-2017
Figure 20: HIV/AIDS Therapeutics Market, Top Five European Countries, Revenue by
Country ($m), 2002-2017
Figure 21: HIV/AIDS Therapeutics Market, Top Five European Countries, Annual Cost of
Therapy ($), 2002-2017
Figure 22: HIV/AIDS Therapeutics Market, Top Five European Countries, Treatment Usage
Patterns, 2002-2017
Figure 23: HIV/AIDS Therapeutics Market, Top Five European Countries, Diseased
Population, 2002-2017
Figure 24: HIV/AIDS Therapeutics Market, Top Five European Countries, Treatment Seeking
Population, 2002-2017
Figure 25: HIV/AIDS Therapeutics Market, Top Five European Countries, Diagnosis
Population, 2002-2017
Figure 26: HIV/AIDS Therapeutics Market, Top Five European Countries, Prescription
Population, 2002-2017
Figure 27: HIV/AIDS Therapeutics Market, Japan, Revenue ($m), 2002-2017
Figure 28: HIV/AIDS Therapeutics Market, Japan, Annual Cost of Therapy ($), 2002-2017
Figure 29: HIV/AIDS Therapeutics Market, Japan, Treatment Usage Patterns, 2002-2017
Figure 30: HIV/AIDS Therapeutics Market, Japan, Diseased Population, 2002-2017
Figure 31: HIV/AIDS Therapeutics Market, Japan, Treatment Seeking Population, 2002-2017
Figure 32: HIV/AIDS Therapeutics Market, Japan, Diagnosis Population, 2002-2017
Figure 33: HIV/AIDS Therapeutics Market, Japan, Prescription Population, 2002-2017
Figure 34: HIV/AIDS Therapeutics Market, Pipeline by Phases of Development (%), 2010
Figure 35: HIV/AIDS Therapeutics Market, Pipeline by Mechanism of Action (%), 2010
Figure 36: HIV/AIDS Therapeutics Market, Global, Competitive Analysis of Major
Manufacturers, Revenues, 2008-2010
Figure 37: HIV/AIDS Therapeutics Market, Gilead, HIV Revenue as Percentage of Total
Revenue, 2010
Figure 38: HIV/AIDS Therapeutics Market, Gliead Sciences Ic, SWOT Analysis, 2010
Figure 39: HIV/AIDS Therapeutics Market, GlaxoSmithKline, HIV Revenue as Percentage of
Total Revenue, 2010
Figure 40: HIV/AIDS Therapeutics Market, GlaxoSmithKline, SWOT Analysis, 2010
Figure 41: HIV/AIDS Therapeutics Market, Bristol-Myers-Squibb, HIV Revenue as
Percentage of Total Revenue, 2010
Figure 42: HIV/AIDS Therapeutics Market, Bristol-Myers Squibb, SWOT Analysis, 2010
Figure 43: HIV/AIDS Therapeutics Market, Abbott, HIV Revenue as Percentage of Total
Revenue, 2010
Figure 44: HIV/AIDS Therapeutics Market, Abbott Laboratories, SWOT Analysis, 2010
Figure 45: HIV/AIDS Therapeutics Market, Merck, HIV Revenue as Percentage of Total
Revenue, 2010
Figure 46: HIV/AIDS Therapeutics Market, Merck, SWOT Analysis, 2010
Figure 47: HIV/AIDS Therapeutics Market, Pfizer, SWOT Analysis, 2010
Figure 48: HIV/AIDS Therapeutics Market, Global, Deals by Geography and Type, 2009-
2010
Figure 49: HIV/AIDS Therapeutics Market, Global, M&A Deals, 2009-2010
Figure 50: HIV/AIDS Therapeutics Market, Global, Major Licensing Agreements by Phase,
2009-2010
Figure 51: GBI Research Market Forecasting Model

About Us:

ReportsnReports is an online library of over 100,000+ market research reports and in-depth
market research studies & analysis of over 5000 micro markets. We provide 24/7 online and
offline support to our customers. Get in touch with us for your needs of market research
reports.

Follow us on Twitter: http://twitter.com/marketsreports

Contact:
Mr.Priyank
7557 Rambler road,
Suite727,Dallas,TX75231
Tel: + 1 888 391 5441
E-mail: sales@reportsandreports.com

								
To top